OncoMatch/Clinical Trials/NCT06476184
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
Is NCT06476184 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Carboplatin and Paclitaxel for ovarian cancer.
Treatment: Carboplatin · Paclitaxel — SALVOVAR will be a pragmatic open-label multicenter randomized phase III trial (ratio 1:1) comparing the efficacy of the salvage weekly dose-dense regimen with those of the continuation of the standard regimen.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage III, IV
Grade: high-grade
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy (carboplatin, paclitaxel) — neo-adjuvant, first-line
Treated with 3 to 4 neo-adjuvant cycles of standard 3-weekly carboplatin-paclitaxel regimen in first-line setting
Cannot have received: VEGF inhibitor (bevacizumab)
Previous treatment with bevacizumab during initial standard neo-adjuvant chemotherapy
Cannot have received: investigational agent
Treatment with other investigational agents in clinical trials.
Lab requirements
Blood counts
Hemoglobin ≥8 g/dL without red blood cell transfusion within 3 weeks before the blood work; ANC ≥1500 cells/mm3; Platelet count ≥100,000/mm3
Kidney function
Creatinine clearance ≥40 mL/min/1.73 m2 (measured or estimated, ideally with CKD-EPI formula)
Liver function
AST and ALT ≤2.5 × ULN, or ≤5 × ULN in context of liver metastases; total bilirubin ≤1.5 × ULN (≤3 × ULN if Gilbert's); albumin ≥3 g/dL
Adequate organ and bone marrow function for weekly-dense chemotherapy: red blood cells (baseline Hemoglobin ≥8 g/dL without red blood cell transfusion within 3 weeks before the blood work), white blood cells (Absolute neutrophil count (ANC) ≥1500 cells/mm3) and platelets (Platelet count ≥100,000/mm3), Adequate renal and liver functions: AST and ALT ≤2.5 × ULN, or ≤5 × ULN in context of liver metastases; total bilirubin ≤1.5 × ULN (≤3 × ULN if Gilbert's); albumin ≥3 g/dL; Creatinine clearance ≥40 mL/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify